Loading the section…

OFIX: financial statements from SEC — TradeAlmanac

OFIX

Orthofix Medical Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/12/2025	31/12/2024
Revenue	822M	799M
Cost of revenue	256M	254M
Gross profit	566M	546M
Research and development	66M	74M
Selling, general and administrative	554M	533M
Operating income	−81M	−85M
Pre-tax income	−91M	−124M
Income tax	1M	2M
Net income	−92M	−126M
Earnings per share	−2.33	−3.30
Earnings per share, diluted	−2.33	−3.30
Weighted average shares	40M	38M
Weighted average shares, diluted	40M	38M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	120M	82M	63M	66M	58M	83M	30M	26M
Receivables	138M	136M	131M

Cash flow

Metric	31/12/2025	31/12/2024
Operating cash flow	33M	26M
Depreciation and amortisation	—	60M
Share-based compensation	29M	32M
Capital expenditure	35M	35M
Investing cash flow	−35M	−28M
Financing cash flow	−786,000

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator